Overview
Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Acute or Chronic Gastritis
Status:
Enrolling by invitation
Enrolling by invitation
Trial end date:
2021-12-31
2021-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of study is to confirm the efficacy of DWP14012 X mg QD, DWP14012 Y mg BID compared to placebo in patients with Acute or Chronic GastritisPhase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Daewoong Pharmaceutical Co. LTD.
Criteria
Inclusion Criteria:- Adults between 19 and 75 years old based on the date of written agreement
- Those who are diagnosed with acute or chronic gastritis with at least one erosion
observed on upper gastrointestinal endoscopy
- Those who had experienced one or more subjective symptoms of gastritis
Exclusion Criteria:
- Those who have had surgery to reduce gastric acid secretion, or gastric or esophageal
surgery
- Those with history of clinically significant hepatic, renal, neurologic, pulmonary,
endocrine, hematologic, cardiovascular or genitourinary disease that could affect the
study results